PLOS ONE

Seroprevalence of brucellosis and characterisation of *Brucella* spp. from slaughtered cattle in Rwanda

--Manuscript Draft--

Manuscript Number:	
Article Type:	Research Article
Full Title:	Seroprevalence of brucellosis and characterisation of <i>Brucella</i> spp. from slaughtered cattle in Rwanda
Short Title:	Characterization of <i>Brucella</i> species from slaughtered cattle in Rwanda
Corresponding Author:	Jean Bosco Ntivuguruzwa, MSc University of Rwanda College of Agriculture Animal Sciences and Veterinary Medicine Kigali , RWANDA
Keywords:	Abattoirs; <i>Brucella</i> spp.; cattle; culture; PCR; serology; Rwanda
Abstract:	Bovine brucellosis is endemic in Rwanda, although, there is paucity of documented evidence about the disease in slaughtered cattle. A cross-sectional study was conducted in slaughtered cattle (n=300) to determine the seroprevalence of anti- <i>Brucella</i> antibodies using the Rose Bengal Test (RBT), and indirect enzyme-linked immunosorbent assay (i-ELISA). Corresponding tissues were cultured onto a modified Centro de Investigación y Tecnología Agroalimentaria (CITA) selective medium and analysed for <i>Brucella</i> spp. using the 16S-23S ribosomal interspacer region (ITS), AMOS, and Bruce-ladder PCR assays. The RBT seroprevalence was 20.7% (62/300), and 2.9% (8/300) with i-ELISA and 2.9% (8/300) using both tests in parallel. <i>Brucella</i> specific 16S-23S ribosomal DNA interspace region (ITS) PCR detected <i>Brucella</i> DNA in 5.6% (17/300; <i>Brucella</i> culture prevalence). AMOS-PCR assay identified mixed <i>B. abortus</i> and <i>B. melitensis</i> (n=3), <i>B. abortus</i> (n=3) and <i>B. melitensis</i> (n=5) while Bruce-ladder PCR also identified <i>B. abortus</i> (n=5) and <i>B. melitensis</i> (n=6). The gold standard culture method combined with PCR confirmation identified 5.6% <i>Brucella</i> cultures which is higher than the more sensitive seroprevalence of 2.9%. This emphasizes the need to validate the serological tests in Rwanda. The mixed infection caused by <i>B. abortus</i> and <i>B. melitensis</i> in slaughtered cattle indicates cross-infection and poses a risk of exposure potential to abattoir workers. It is essential to urgently strengthen the national bovine brucellosis control program through vaccination as well as test-and-slaughter.
Order of Authors:	Jean Bosco Ntivuguruzwa, MSc Francis Babaman Kolo, P.h.D Ivan Emil Mwikarago, P.h.D Henriette vanHeerden, P.h.D
Opposed Reviewers:	Karama Karama, Ph.D Senior lecturer, University of Pretoria Faculty of Veterinary Science musafiri.karama@up.ac.za He has been very bad to me when I was doing my masters. He refused me to publish my three articles.
Additional Information:	
Question	Response
Financial Disclosure Enter a financial disclosure statement that describes the sources of funding for the work included in this submission. Review the submission guidelines for detailed requirements. View published research	HvH received funds from the Institute of Tropical Medicine Antwerp (https://www.itg.be) in collaboration with the Department of Veterinary Tropical Diseases (https://www.up.ac.za/veterinary-tropical-diseases).

articles from [PLOS ONE](#) for specific examples.

This statement is required for submission and **will appear in the published article** if the submission is accepted. Please make sure it is accurate.

Unfunded studies

Enter: *The author(s) received no specific funding for this work.*

Funded studies

Enter a statement with the following details:

- Initials of the authors who received each award
- Grant numbers awarded to each author
- The full name of each funder
- URL of each funder website
- Did the sponsors or funders play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript?
- **NO** - Include this sentence at the end of your statement: *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*
- **YES** - Specify the role(s) played.

* typeset

Competing Interests

Use the instructions below to enter a competing interest statement for this submission. On behalf of all authors, disclose any [competing interests](#) that could be perceived to bias this work—acknowledging all financial support and any other relevant financial or non-financial competing interests.

This statement is **required** for submission and **will appear in the published article** if the submission is accepted. Please make sure it is accurate and that any funding sources listed in your Funding Information later in the submission form are also declared in your Financial Disclosure statement.

The authors declare that there are no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

<p>View published research articles from PLOS ONE for specific examples.</p> <p>NO authors have competing interests</p> <p>Enter: <i>The authors have declared that no competing interests exist.</i></p> <p>Authors with competing interests</p> <p>Enter competing interest details beginning with this statement:</p> <p><i>I have read the journal's policy and the authors of this manuscript have the following competing interests: [insert competing interests here]</i></p> <p>* typeset</p>	
<p>Ethics Statement</p> <p>Enter an ethics statement for this submission. This statement is required if the study involved:</p> <ul style="list-style-type: none"> • Human participants • Human specimens or tissue • Vertebrate animals or cephalopods • Vertebrate embryos or tissues • Field research <p>Write "N/A" if the submission does not require an ethics statement.</p> <p>General guidance is provided below. Consult the submission guidelines for detailed instructions. Make sure that all information entered here is included in the Methods section of the manuscript.</p>	<p>The authorization to conduct the study was obtained from the research screening and ethical clearance committee of the College of Agriculture, Animal Sciences and Veterinary Medicine, University of Rwanda (Ref:026/DRIPGS/2017), institutional review board of the College of Medicine and Health Sciences, University of Rwanda (No 006/CMHS IRB/2020), and Animal Ethics Committee of the Faculty of Veterinary Science, University of Pretoria, South Africa (V004/2020).</p>

Format for specific study types

Human Subject Research (involving human participants and/or tissue)

- Give the name of the institutional review board or ethics committee that approved the study
- Include the approval number and/or a statement indicating approval of this research
- Indicate the form of consent obtained (written/oral) or the reason that consent was not obtained (e.g. the data were analyzed anonymously)

Animal Research (involving vertebrate animals, embryos or tissues)

- Provide the name of the Institutional Animal Care and Use Committee (IACUC) or other relevant ethics board that reviewed the study protocol, and indicate whether they approved this research or granted a formal waiver of ethical approval
- Include an approval number if one was obtained
- If the study involved *non-human primates*, add *additional details* about animal welfare and steps taken to ameliorate suffering
- If anesthesia, euthanasia, or any kind of animal sacrifice is part of the study, include briefly which substances and/or methods were applied

Field Research

Include the following details if this study

involves the collection of plant, animal, or

other materials from a natural setting:

- Field permit number
- Name of the institution or relevant body that granted permission

Data Availability

Authors are required to make all data underlying the findings described fully available, without restriction, and from the time of publication. PLOS allows rare exceptions to address legal and ethical concerns. See the [PLOS Data Policy](#) and [FAQ](#) for detailed information.

Yes - all data are fully available without restriction

A Data Availability Statement describing where the data can be found is required at submission. Your answers to this question constitute the Data Availability Statement and **will be published in the article**, if accepted.

Important: Stating 'data available on request from the author' is not sufficient. If your data are only available upon request, select 'No' for the first question and explain your exceptional situation in the text box.

Do the authors confirm that all data underlying the findings described in their manuscript are fully available without restriction?

Describe where the data may be found in full sentences. If you are copying our sample text, replace any instances of XXX with the appropriate details.

- If the data are **held or will be held in a public repository**, include URLs, accession numbers or DOIs. If this information will only be available after acceptance, indicate this by ticking the box below. For example: *All XXX files are available from the XXX database (accession number(s) XXX, XXX).*
- If the data are all contained **within the manuscript and/or Supporting Information files**, enter the following:
All relevant data are within the manuscript and its Supporting Information files.
- If neither of these applies but you are able to provide **details of access elsewhere**, with or without limitations, please do so. For example:

Data cannot be shared publicly because of [XXX]. Data are available from the XXX Institutional Data Access / Ethics Committee (contact via XXX) for researchers who meet the criteria for access to confidential data.

The data underlying the results presented in the study are available from (include the name of the third party

All relevant data are within the manuscript and its Supporting Information files.

<p><i>and contact information or URL).</i></p> <ul style="list-style-type: none"> • This text is appropriate if the data are owned by a third party and authors do not have permission to share the data. <p>* typeset</p>	
<p>Additional data availability information:</p>	<p>Tick here if your circumstances are not covered by the questions above and you need the journal's help to make your data available.</p>

**College of Agriculture and Veterinary Medicine,
Department of Veterinary Medicine**

December 4th, 2021

To: Editor/ PLOS ONE

Re: Submission of manuscript

Enclosed is a manuscript to be considered for publication in PLOS ONE. The title of the manuscript is “seroprevalence of brucellosis and molecular characterization of *Brucella* spp. from slaughtered cattle in Rwanda”. Bovine brucellosis is a zoonotic disease that is prevalent in the cattle population in Rwanda. However, there is not sufficient data about the seroprevalence and *Brucella* spp. circulating in Rwandan cattle. We investigated the seroprevalence of brucellosis and characterized *Brucella* spp. from slaughtered cattle in Rwanda. Our findings demonstrated the overall seroprevalence of 2.9% (8/300) using the Rose Bengal Test and indirect ELISA in parallel. The culture prevalence confirmed with *Brucella* specific 16S-23S ribosomal DNA interspace region (ITS) PCR was 5.6% (17/300). AMOS-PCR assay identified mixed *B. abortus* and *B. melitensis* (n=3), *B. abortus* (n=3) and *B. melitensis* (n=5) while Bruce-ladder PCR confirmed *B. abortus* (n=5) and *B. melitensis* (n=6). The gold standard culture method combined with PCR confirmation (5.6%) was higher than the more sensitive seroprevalence of 2.9%. This emphasizes the need to validate the serological tests in Rwanda. The mixed infection caused by *B. abortus* and *B. melitensis* in slaughtered cattle indicates cross-infection and poses a risk of exposure potential to abattoir workers. It is essential to urgently strengthen the national bovine brucellosis control program through vaccination as well as test-and-slaughter.

This manuscript is an original work that meets the scope and aims of the PLOS ONE and has not been submitted to any journal for publication.

I am Jean Bosco Ntivuguruzwa, a corresponding author on behalf of all other co-authors.

Yours sincerely

A handwritten signature in black ink, appearing to read 'Jean Bosco Ntivuguruzwa', with a horizontal line underneath.

Jean Bosco Ntivuguruzwa, the corresponding Author

Seroprevalence of brucellosis and molecular characterization of *Brucella* spp. from slaughtered cattle in Rwanda

Jean Bosco Ntivuguruzwa^{1, 2 ¶}; Francis Babaman Kolo^{1&}; Emil Ivan Mwikarago^{3#a &}; Henriette vanHeerden^{1¶}

¹Department of Veterinary Tropical Diseases, Faculty of Veterinary Science, University of Pretoria; Pretoria, South Africa

²Department of Veterinary Medicine, College of Veterinary Medicine, University of Rwanda, Kigali, Rwanda

³Department of Biomedical Services, National Reference Laboratory Division, Rwanda Biomedical Centre, Kigali, Rwanda

^{#a}Current address: Department of Lab Sciences, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda

* Corresponding author

Corresponding author: boscus2@gmail.com, +250788648909

¶ These authors contributed equally to this work

& These authors also contributed equally to this work

Abstract

Bovine brucellosis is endemic in Rwanda, although, there is paucity of documented evidence about the disease in slaughtered cattle. A cross-sectional study was conducted in slaughtered cattle (n=300) to determine the seroprevalence of anti-*Brucella* antibodies using the Rose Bengal Test (RBT), and indirect enzyme-linked immunosorbent assay (i-ELISA). Corresponding tissues were cultured onto a modified Centro de Investigación y Tecnología Agroalimentaria (CITA) selective medium and analysed for *Brucella* spp. using the 16S-23S ribosomal interspacer region (ITS), AMOS, and Bruce-ladder PCR assays. The RBT seroprevalence was 20.7% (62/300), and 2.9% (8/300) with i-ELISA and 2.9% (8/300) using both tests in parallel. *Brucella* specific 16S-23S ribosomal DNA interspace region (ITS) PCR detected *Brucella* DNA in 5.6% (17/300; *Brucella* culture prevalence). AMOS-PCR assay identified mixed *B. abortus* and *B. melitensis* (n=3), *B. abortus* (n=3) and *B. melitensis* (n=5) while Bruce-ladder PCR also identified *B. abortus* (n=5) and *B. melitensis* (n=6). The gold standard culture method combined with PCR confirmation identified 5.6% *Brucella* cultures which is higher than the more sensitive seroprevalence of 2.9%. This emphasizes the need to validate the serological tests in Rwanda. The mixed infection caused by *B. abortus* and *B. melitensis* in slaughtered cattle indicates cross-infection and poses a risk of exposure potential to abattoir workers. It is essential to urgently strengthen the national bovine brucellosis control program through vaccination as well as test-and-slaughter.

Keywords

Abattoirs; *Brucella* spp.; cattle; culture; PCR; serology; Rwanda

Introduction

Brucellosis is a contagious widespread disease that causes not only substantial economic losses related to abortions, long conception intervals, and sterility in animals but also morbidity and reduced working capacity in humans (1, 2). The disease is caused by bacteria of the genus *Brucella* which belongs to the family of alphaproteobacteria (3). *Brucella* species are gram-negative microaerophilic coccobacilli, acid-fast intracellular, and hosts-specific microorganisms affecting a wide variety of terrestrial and marine mammals (4, 5). *Brucella* species are 96% genetically identical (6) with few polymorphisms that are essential for species and biovars differentiation (7, 8). Classical species with their biovars (bv.) have specific hosts, for instance, *B. abortus* (7 biovars) infect primarily cattle, *B. melitensis* (3 biovars) infect goats and sheep, *B. ovis* infect sheep, *B. suis* (bv. 1, 3, 4, and 5) infect swine while *B. suis* bv. 2 infects rats, *B. canis* infects dogs, and *B. neotomae* infects wood rats (4, 9).

The transmission of brucellosis in animals is through inhalation of *Brucella* aerosols (10), direct contact with infective foetal membranes, vaginal discharges, placenta content, and ingestion of contaminated feeds (11). There are no pathognomonic clinical signs for brucellosis, but cases of abortion or hygroma are suspicious signs that require laboratory diagnosis for confirmation (9, 12).

As brucellosis is a herd disease, the most suitable tests are serological tests to determine the seroprevalence of brucellosis in the animal and or herd using a screening agglutination test, the Rose Bengal Test (RBT), and a confirmatory test like enzyme-linked immunosorbent assays

(ELISAs) or complement fixation test (CFT) (9). However, serological tests do not provide a complete diagnosis, thus, the isolation of *Brucella* spp. remains the gold standard (9). The culturing and biotyping of *Brucella* cultures are expensive, time-consuming, and require trained personnel (7). PCR assays which differentiate *B. abortus* bv.1, 2, 4, *B. melitensis* bv.1, 2, 3, *B. ovis*, and *B. suis* bv.1 (AMOS PCR) in 24 hours from cultures (7) and Bruce-ladder PCR assay can differentiate all *Brucella* species and vaccine strains (13, 14). Unfortunately, culture, phenotypic and genotypic isolation of *Brucella* spp. are not common in veterinary services in most developing countries owing to inadequate facilities and trained personnel; therefore, serology is in common practice with little knowledge on the type of infecting *Brucella* spp. (15).

Brucellosis is an endemic disease in Rwanda with a reported 7.4% to 18.7% seroprevalence in cattle (16, 17), as well as seroprevalence in women with a history of abortions varying between 6.1% and 25.0% (18, 19). Although, cattle from various districts of the country are slaughtered at abattoirs, there is no single study on the seroprevalence of brucellosis in slaughtered cattle in Rwanda. Furthermore, apart from a single study that isolated *B. abortus* bv. 3 from Rwandan cattle in the 1980s (20), *Brucella* spp. that are circulating in Rwanda are not known. The objective of this study was, therefore, to determine the seroprevalence of brucellosis and characterize *Brucella* spp. from slaughtered cattle in Rwanda. Our findings are essential to building an epidemiological database essential for the control of brucellosis in Rwanda.

Materials and methods

Study area

This study was conducted at six abattoirs in Rwanda. Rwanda is a landlocked country of the East African community covering an area of 26,338 Km² in the southern hemisphere near the equator (West: 28.86; East: 30.89; North: - 1.04; South: - 2.83). The bovine population in Rwanda was estimated at 1,293,768 in 2018 (21). The six abattoirs (société des abattoirs de Nyabugogo “SABAN”, Rugano abattoir, Kamembe, Rubavu, Kamuhanda, Gataraga) consented to participate (Fig 1). These abattoirs were selected based on their slaughtering capacity and their location to sample cattle from all the thirty districts of Rwanda. In this study, cattle sampled at SABAN abattoir were from 19 districts including Rulindo, Ngoma, Muhanga, Nyagatare, Gasabo, Bugesera, Ngororero, Gakenke, Burera, Rutsiro, Gicumbi, Nyarugenge, Kirehe, Ruhango, Kayonza, Karongi, Nyanza, Kamonyi, and Gatsibo. Cattle sampled at Rugano abattoir were from three districts including Gasabo, Rwamagana, and Nyarugenge. Cattle sampled at Kamembe abattoir were from eight districts including Gisagara, Huye, Nyamagabe, Nyamasheke, Nyanza, Nyaruguru, Ruhango, and Rusizi. Cattle sampled at Rubavu abattoir were from two districts including Nyabihu, and Rubavu. Cattle sampled at Kamuhanda abattoir were from the Kamonyi district. Cattle sampled at Gataraga abattoir were from the Musanze district. These abattoirs were classified into high throughput abattoirs (n = 4) slaughtering more than 50 cattle daily and low throughput abattoirs (n = 2) slaughtering 50 or less every day.

Fig 1. Map of provinces and districts of Rwanda with location (red asterisks) of abattoirs visited during this study.

Study design and sample size

A cross-sectional study was carried out from August 2018 through October 2019 to determine the seroprevalence of brucellosis and characterize *Brucella* spp. from cattle tissue selected during slaughtering at abattoirs. The sample size was calculated using the previously described formula (22) for cross-sectional studies.

$$N = \frac{Z^2 P(1 - P)}{d^2}$$

Where N is the sample size, $Z^2 = 1.96$ the statistical constant at 95% confidence interval; P is the expected prevalence and was estimated at 0.5%, and the absolute precision, $d = (P/2)$. According to the formula, the total sample size was 291 but it was rounded to 300 cattle to sample ten animals per each of the 30 districts of Rwanda.

Sampling procedure

Our target was to sample five animals coming from the same district every day. The district of origin of animals was recorded on arrival using the movement permit issued by the sector animal resources officer at the animal market. The age was determined using teeth erosion as previously described (23). Except for abattoirs that received mostly males, females of one year and above were selected using a systematic random sampling. Animals were aligned in a crush

and every fourth animal was selected for sampling. The vaccination status and farm of origin of slaughtered animals could not be traced because most of the animals were bought from the different animal markets.

Collection of blood and tissues samples

After the selection and recording of individual demographic information (district of origin, age, breed, and sex), the animal was restrained, marked on the head, and released for resting waiting for the collection of blood after bleeding. Blood was collected into sterile 50 ml tubes after slaughter, aliquoted into 5 ml tubes and was immediately transported to the laboratory of the University of Rwanda (UR) and left overnight at room temperature to allow clotting. The following day, serum was collected into a sterile 2 ml micro-centrifuge tube and stored at -20°C until serological testing at Rwanda Agriculture and Animal Resources Board (RAB), Department of Veterinary Services, in the serology section. The head of the marked animal from which blood was collected was followed at head inspection station and the corresponding left and right retropharyngeal lymph nodes were collected into a sterile 50 ml tube.

Serological tests

Animal sera were tested with the RBT following the manufacturer's guidelines (IDvet, France) and the OIE protocol (9). Briefly, equal volumes (30 µl) of *Brucella* antigens and sera were gently mixed for four minutes, and any agglutination was regarded as a positive result. All sera were also checked for the presence of anti-*Brucella* antibodies with a confirmatory test kit namely

a multispecies i-ELISA according to manufacturer's guidelines (IDvet, France) and the OIE protocol (9) with positive and negative controls. The cut-off point for the seropositivity was 120% and sera samples having 120% of optical densities were considered positive. These serological tests were chosen because of their combined effects of sensitivity and specificity (24). RBT is a screening test with high sensitivity, while i-ELISA is a confirmatory test with high specificity (24, 25). Any detection of anti-*Brucella* antibodies by RBT or i-ELISA was considered to determine the seroprevalence of brucellosis.

Culturing and *Brucella* isolation from tissues

Tissue samples were processed and cultured in a biosafety level 3 (BSL 3) facility at the National Reference Laboratory (NRL), Rwanda Biomedical Centre (RBC), Kigali, Rwanda according to the guidelines previously described (9). Briefly, tissues were sliced using sterile scissors and forceps into sterile mortars and grounded using a sterile pestle. An aliquot of pooled homogenate was spread into a modified Centro de Investigación y Tecnología Agroalimentaria (CITA) selective medium and incubated at 37°C with 10.0% CO₂ atmosphere (26). Plates were read for bacterial growth every day for four weeks. The DNA was extracted from colonies suspect of *Brucella* organisms.

DNA extraction and identification of the genus *Brucella* spp.

Genomic DNA was extracted from cultures using the ReliaPrep gDNA tissue Miniprep system following the manufacturer's guidelines (Promega, USA). This DNA was screened for

Brucella DNA using *Brucella* specific primers (Table 1) designed from a gene-specific 16S -23S rDNA interspacer region (ITS) (27) with the *B. abortus* RF 544 (Onderstepoort Biological Products, South Africa) as a positive control. The 15 µl PCR reaction mixture contained 1x of MyTaq™ Red PCR Mix (Bioline, South Africa), primers at 0.2 µM, and 2 µl of template DNA. The PCR cycling condition was initial denaturation at 95°C for 3 min followed by 35 cycles of denaturation at 95°C for 1 min, annealing at 60°C for 2 min, and extension at 72°C for 2 min and a final extension step at 72°C for 5 min. The primers amplified a 214 bp fragment that was analyzed by electrophoresis using a 2% agarose gel stained with red gel nucleic acid stain and visualized under UV light. Molecular analyses were done at the Department of Veterinary Services, Rwanda Agriculture Board (RAB) Kigali, Rwanda.

Identification of *Brucella* species using AMOS and Bruce-ladder PCR assays

The DNA samples that were ITS PCR positive were tested for *B. abortus*, *B. melitensis*, *B. ovis*, and *B. suis* using a multiplex AMOS PCR assay as previously described (7). A 25 µl reaction mixture contained 1x MyTaq Red PCR Mix (Bioline, South Africa), four species-specific forward primers and reverse primer IS711 (Table 1) at a final concentration of 0.1 µM and 0.5 µM respectively, and 2 µl of template DNA. Thermocycling conditions included initial denaturation at 95°C for 3 min followed by 35 cycles of denaturation at 95°C for 1 min, annealing at 60°C for 2 min, an initial extension at 72°C for 2 min, and a final extension at 72°C for 5 min. PCR products

were analysed by gel electrophoresis using 2% agarose stained with red gel nucleic acid stain and visualized under UV light.

Vaccine strains and field isolates of *Brucella* spp. were identified and differentiated by a multiplex Bruce-ladder PCR as previously described (14). A 25 µl PCR reaction contained 1x MyTaq™ Red Mix (Bioline, South Africa), eight species-specific forward and reverse primers at a final concentration of 6.25 µM (Table 1), and 5 µl of template DNA. The PCR cycling conditions included an initial denaturation at 95°C for 5 min followed by 25 cycles of at 95°C for 30 s, at 64°C for 45 s, and at 72°C for 3 min and a final extension step at 72°C for 10 min. PCR products were analysed by gel electrophoresis using a 2% agarose stained with gel red nucleic acid stain and viewed under UV light.

Data analysis

The overall seroprevalence was obtained by dividing the total number of animals simultaneously positive to RBT and i-ELISA by the total number of animals sampled. Data were recorded in Microsoft Excel spreadsheets. Epi-Info 7 version 10 was used to calculate proportions. Significant levels between individual risk factors and seroprevalence and molecular results were determined using the chi-square test. The odds-ratios were determined for associated risk factors along 95% confidence intervals and statistical significance set at $p < 0.05$.

Ethics clearance

189 The authorization to conduct the study was obtained from the research screening and
190 ethical clearance committee of the College of Agriculture, Animal Sciences and Veterinary
191 Medicine, University of Rwanda (Ref:026/DRIPGS/2017), institutional review board of the
192 College of Medicine and Health Sciences, University of Rwanda (N° 006/CMHS IRB/2020), and
193 Animal Ethics Committee of the Faculty of Veterinary Science, University of Pretoria, South
194 Africa (V004/2020). Informed verbal consent was obtained from managers of abattoirs, and
195 owners of animals at the abattoirs.

196 Table 1: Sequences of oligonucleotide primers used for the distinction of *Brucella* species isolated from slaughtered cattle in Rwanda

197

PCR name	Primer name	Sequence (5'-3')	Targets	Size (bp)	Conc. (μM)	References
ITS	ITS66 f	ACATAGATCGCAGGCCAGTCA	<i>16s-23s</i>	214	0.2	(27)
	ITS279 r	ACATAGATCGCAGGCCAGTCA	<i>rDNA</i>			
AMOS	<i>B. abortus</i>	GAC GAA CGG AAT TTT TCC AAT CCC	IS711	498	0.1	(7)
	<i>B. melitensis</i>	AAA TCG CGT CCT TGC TGG TCT GA		731	0.1	
	<i>B. ovis</i>	CGG GTT CTG GCA CCA TCG TCG GG		976	0.1	
	<i>B. suis</i>	GCG CGG TTT TCT GAA GGT GGT TCA		285	0.1	
	IS 711	TGC CGA TCA CTT AAG GGC CTT CAT			0.2	
BRUCE-LADDER	BMEI0998f	ATC CTA TTG CCC CGA TAA GG	<i>wboA</i>	1682	6.25	(28, 29)
	BMEI0997r	GCT TCG CAT TTT CAC TGT AGC				
	BMEI0535f	GCG CAT TCT TCG GTT ATG AA	<i>bp26</i>	450	6.25	(30)
	BMEI0536r	CGC AGG CGA AAA CAG CTA TAA				
	BMEII0843f	TTT ACA CAG GCA ATC CAG CA	<i>omp31</i>	1071	6.25	(31)
	BMEII0844r	GCG TCC AGT TGT TGT TGA TG				
	BMEI1436f	ACG CAG ACG ACC TTC GGT AT	<i>Deacetylase</i>	794	6.25	(32)
	BMEI1435r	TTT ATC CAT CGC CCT GTC AC				
	BMEII0428f	GCC GCT ATT ATG TGG ACT GG	<i>eryC</i>	587	6.25	(33)
	BMEII0428r	AAT GAC TTC ACG GTC GTTCG				
	BR0953f	GGA ACA CTA CGC CAC CTT GT	<i>ABC Transporter</i>	272	6.25	(34)
	BR0953r	GAT GGA GCA AAC GCT GAA G				
	BMEI0752f	CAG GCA AAC CCT CAG AAG C	<i>rpsL</i>	218	6.25	(35)
	BMEI0752r	GAT GTG GTA ACG CAC ACC AA				
	BMEII0987f	CGC AGA CAG TGA CCA TCA AA	<i>CRP Regulator</i>	152	6.25	(32)
	BMEII0987r	GTA TTC AGC CCC CGT TAC CT				

198

Results

Brucellosis seroprevalence among slaughter cattle in Rwanda

Of the 300 cattle sera, 95.7% (287/300) were from females, while 4.3% (13/300) were from males. Most animals, 89.7% (269/300) were adults while young animals represented 10.3% (31/300). Twenty-seven percent [27.7%, (81/300)] of cattle sampled were local breed “Ankole”, 67.0% (201/300) were crossbreeds and 5.3% (16/300) were Friesians. Samples were mainly collected from high throughput abattoirs (n=280) compared to low throughput abattoirs (n=20). The seroprevalence of brucellosis in parallel was 20.7% (62/300) and 2.9% (8/300) using RBT and i-ELISA, respectively. The seroprevalence was 2.9%, (8/300) using both tests in parallel. Twenty-one percent [21.1%, (59/280)] of the RBT positive cattle were sampled from high throughput abattoirs, while 15.0% (3/20) were from the low throughput abattoirs. Eight samples that were simultaneously positive on RBT and i-ELISA were collected from high throughput abattoirs (Table 2). Considering the RBT results alone, the highest RBT positivity rate of 30.0%, (21/70) was observed in the Eastern Province while the lowest 13.3%, (4/30) was recorded in the Kigali city (Table 2). Twenty-one percent [21.6%, (58/269)] of RBT seropositive animals were adult, while 12.9%, (4/31) were young. Twenty percent [20.6%, (59/287)] of RBT seropositive animals were female while 23.1%, (3/13) were young. The eight animals that were seropositive to both tests were adult females. The RBT seropositivity recorded in different breeds of animals was as follows: 15.7%, (13/83) for Ankole, 22.0%, (44/201) for crossbreeds and 31.3%, (5/16) for Friesians with no significant statistical difference ($p = 0.28$). However, there was a significant association (p

219 = 0.04) between seropositivity (RBT and i-ELISA) and breeds with Friesian being more
 220 seropositive 12.5%, (2/16) than crossbreds 2.5%, (5/201) and Ankole 1.2%, (1/83) (Table 1).

Table 2: Univariate associations between animal characteristics, seropositivity, and isolation of *Brucella* spp. using ITS PCR assay on the DNA extracted from cultures of tissues of slaughtered cattle in Rwanda.

Variables	Categories	Tested	RBT			i-ELISA			ITS PCR assay on culture isolates		
			n+ (%)	OR	p-value	n+ (%)	OR	p-value	n+ /N (%)	OR	p-value
Abattoirs	High thr.	280	59 (21.1)	0.8 – 1.1	0.78	8 (2.9)	0.1-0.2	1	16/78 (20.5)	0.69-1.16	0.68
	Low thr.	20	3 (15.0)			0 (0.0)			1/9 (11.1)		
Provinces	Eastern	70	21 (30.0)	-	0.17	3 (4.3)	-	0.37	2/14 (14.3)	-	0.95
	Kigali city	30	4 (13.3)			3 (6.0)			3/11 (27.3)		
	Northern	50	7 (14.0)			1 (1.3)			4/18 (22.2)		
	Southern	80	14 (17.5)			1 (1.4)			3/17 (17.6)		
	Western	70	16 (22.7)			1 (1.4)			5/27 (18.5)		
Age	Adults	269	58 (21.6)	0.8 – 1.0	0.35	8 (3.0)	0.95-0.99	1	17/77 (22.1)	0.69-0.88	0.19
	Young	31	4 (12.9)			0 (0.0)			0/10 (0.0)		
Sex	Females	287	59 (20.6)	0.8– 1.4	0.74	8 (2.8)	0.95-0.99	1	17/80 (21.3)	0.70-0.88	0.34
	Males	13	3 (23.1)			0 (0.0)			0/7 (0.0)		
Breed	Ankole	83	13 (15.7)	-	0.28	1 (1.2)	-	0.04	1/21 (4.8)	-	0.02
	Cross	201	44 (22.0)			5 (2.5)			13/61 (21.3)		
	Friesian	16	5 (31.3)			2 (12.5)			3/5 (60.0)		

RBT: Rose Bengal Test, i-ELISA: indirect enzyme-linked immunosorbent assay, Thr. = throughput; OR = odds ratio; CI = confidence interval; n+: number of positives; n+/N: number of positive animals over the total number of tested animals; %: percentage, NaN: not applicable.

Bacteriology and the 16S-23S interspacer region (ITS) PCR assay

Of the tissues (n=300) that were cultured onto the modified CITA medium, ITS PCR confirmed 5.6% (17/300) (Fig 2). Therefore, the prevalence obtained by bacteriology, the gold standard and confirmed by ITS PCR was 5.6% (17/300).

Fig 2. Agarose gel electrophoresis of the 16-23S interspacer region (ITS) PCR products amplified from cultures of tissues from slaughtered cattle. Lanes M: DNA Gene Ruler 100bp plus (Invitrogen, Pretoria, South Africa), lanes 1 – 7: amplification of a 214 bp sequence of the genus *Brucella* spp., lane 8: negative control containing sterile water, lane 9: positive control with *B. abortus* RF544.

Differentiation of *Brucella* spp. by AMOS and Bruce-ladder PCR assays

The AMOS PCR identified *B. melitensis* and *B. abortus* (n=3) mixed cultures, *B. abortus* (n=3) and *B. melitensis* (n=5) (Fig 3) from the 17 *Brucella* cultures (impure culture). The Bruce-ladder PCR assay identified *B. abortus* (n=5), *B. melitensis* (n=6) (Fig 4).

Fig 3. Agarose gel electrophoresis for AMOS PCR products amplified from cultures of tissues from slaughtered cattle. Lanes M: Gene Ruler 100 pb plus (Invitrogen, ThermoFischer, South Africa), lanes 1-4: *Brucella abortus* (496 bp), lanes 5-7: *B. melitensis* (731 bp), Lanes 9-10: mixed *B. melitensis* and *B. abortus*, lane 11: negative control containing sterile water, lane 12: positive control, *B. abortus* RF544, lane 13: positive control, *B. melitensis* rev 1.

Fig 4. Agarose gel electrophoresis for Bruce-ladder PCR products amplified from cultures of tissues from slaughtered cattle. Lanes M: Gene Ruler 100 bp (Invitrogen, ThermoFischer, South Africa); lanes 1-5: *B. abortus*; lanes 6-8: *B. melitensis*; lane 9: positive control, *B. suis* ZW45, lane 10: positive control, *B. melitensis* rev 1, lane 11: *B. abortus* (REF 544), lane 12: positive control, *B. abortus* S 19, lane 13: negative control with sterile water.

Culture prevalence amongst slaughtered cattle in Rwanda

The *Brucella* culture prevalence obtained by culture and confirmed by ITS PCR was 5.6% (17/300). Of the *Brucella* spp. obtained by culture, 20.5% (16/78) were collected from high throughput abattoirs, while 11.1% (1/9) were from low throughput abattoirs (OR = 0.69 – 1.16, $p = 0.68$). There was no significant association between the isolation of *Brucella* spp. isolates and the provinces of origin ($p = 0.95$), and the isolates were collected from the provinces as follows: Eastern (14.3%, 2/14), Kigali city (27.3%, 3/11), Northern (22.2%, 4/18), Southern (17.6%, 3/17), Western (18.5%, 5/27). All the *Brucella* obtained by culture (21.3%, 17/80) were adult (OR = 0.69 - 0.88, $p = 0.20$) and females (OR = 0.70 - 0.88, $p = 0.34$). There was a significant association between the culture prevalence and breed ($p = 0.02$) with Friesians having more isolates (60.0%, 3/5), followed by crossbreds (21.3%, 13/61) and Ankole (4.8%, 1/21) (Table 2).

The *Brucella* DNA detected by ITS, AMOS and Bruce-ladder PCR assays (100.0%, 11/11) were from cattle that were either seropositive to RBT or i-ELISA. Of these 11 *Brucella* isolates, 10 were isolated from slaughtered cattle collected at high throughput abattoir. The 11 *Brucella* isolates that were identified in provinces are as follows: Eastern ($n = 1$),

265 Kigali city (n = 2), Southern (n = 3), Western (n = 2), Northern (n = 3). The 11 *Brucella*
 266 isolates stratified by breeds were Ankole (n = 1), crossbreds (n = 8) and Friesians (n = 2).
 267 There was no significant difference between the category of abattoirs, provinces, age, sex
 268 of animals and the detection by ITS, AMOS and Bruce-ladder PCR assays.

Discussion

This is the first report of *B. abortus* and *B. melitensis* isolated from cultures of cattle tissues collected from abattoirs. The overall seroprevalence obtained in this study among slaughtered cattle selected from all the thirty districts of Rwanda (2.9% for RBT and i-ELISA) was lower than the culture prevalence of 5.6% (17/300), which is the gold standard. The fact that the lower sensitivity culture method is higher than the seroprevalence is a clear indication that the confirmatory i-ELISA test must be validated for bovine in Rwanda as the cut-off values were determined in developed countries with low brucellosis prevalence and thus clearly underestimate the prevalence due to high cut-off values.

The overall seroprevalence of 2.9% was also lower than the rates reported in Rwanda in different studies that were conducted at farm level (16, 17, 36). However, the seroprevalence obtained in this study is comparable with the rate (3.4%) reported at Gaoundere municipal abattoir in Cameroun using RBT and i-ELISA (37), and the 3.9% reported among slaughtered cattle in Nigeria (38), and the 5.5% reported among slaughtered cattle in Gauteng province, South Africa (39). This suggests that the seroprevalence rates observed in abattoirs are usually lower compared to the seroprevalence recorded at the farm level which usually focuses on endemic zones while slaughtered cattle come from various locations (endemic and non-endemic zones).

Friesians were more likely to be seropositive in this study and was consistent with earlier studies in Pakistan where Holstein and Friesian cattle were more seropositive than indigenous breeds (40), and in Ethiopia (41). This supports that exotic pure breeds like Friesians are more susceptible to brucellosis than crossbreeds and indigenous breeds (42) or were introduced in the

herd with chronic infections with seronegative status but being chronically infected (12, 43).
When the acute brucellosis phase has passed, the infection stabilizes with the acquisition of herd
immunity leading to less infectious discharges and non-visible symptoms (44).

The mixed infection caused by *B. abortus* and *B. melitensis* and the isolation of *B. melitensis*
from slaughtered cattle indicate the cross-infection between both *Brucella* spp. and mixed farming
of cattle and goats or sheep. The mixed infection and mixed farming were reported in our study
that identified both pathogens in aborting goat flock in Rwanda (unpublished data). The co-
infection of *B. abortus* and *B. melitensis* has also been reported in slaughtered cattle in South Africa
(39). The isolation of *B. melitensis* in slaughtered cattle poses a risk to abattoir workers and
consumers of contaminated milk and milk products as *B. melitensis* and *B. abortus* cause severe
brucellosis in humans (45, 46). There is a need for improvement in brucellosis control using
vaccination as well as test-and-slaughter, coupled with raising awareness of all occupational
groups as education was associated with a high awareness of brucellosis in Rwanda (17).

Both AMOS and Bruce-ladder PCR assays identified *B. abortus* and *B. melitensis* with the
B. abortus being either biovars 1, 2, or 4 (identified by AMOS PCR) which will be identified in the
future after purification of cultures using biotyping. A previous study *B. abortus* bv. 3 was
identified in humans and animals in 1987 in Rwanda (20). *B. abortus* bv. 3 and *B. melitensis* bv. 1
were reported in neighboring Uganda (47), Tanzania (48), Kenya (49) and South Africa (39).
Biotyping of *B. abortus* biovars is complex as characteristic typical for *B. abortus* bv. 1, except CO₂
requirement for growth (50). However, the *B. abortus* bv. 3 ref strain Tulya isolated from human
patient in Uganda grows in the absence of CO₂ and has been observed to occur within some

biovars and changes with OIE biotyping profile (9, 48). Hence classifying *B. abortus* bv. 3 strains should be carefully considered. Purifying and biotyping these cultures will be able to identify the biovar(s) and molecular characterization of the strains will allow trace back studies. *Brucella abortus* and *B. melitensis* isolated in this study could originate from neighboring countries due to repatriation of Rwandans and their livestock from Uganda and Tanzania as well as importation of improved cattle breeds from various countries cannot be eliminated despite testing procedures (12).

Brucella spp. were mostly isolated from adult females, and this is not surprising as cattle industry focuses mostly on dairy production while commercial beef production is emerging in Rwanda. Almost half (47.0%) of the milk produced in 2008 was destined for sale at the informal market, with 16.0% for home consumption, while 35.0% represented spoiled milk (51). Therefore, the occurrence of brucellosis in slaughtered cattle is not only a risk to abattoir workers but also consumers of milk and milk products. Several cattle and tons of beef are sold to Bukavu and Goma, the towns of the Democratic Republic of Congo neighbouring Rwanda where the brochettes of the udder are expensive and frequently consumed. The udder is among the predilection sites of *Brucella* spp. (52, 53) and meat inspection should focus on the udder. Meat inspection provides safe meat and contributes to the monitoring and surveillance for animal infectious diseases and zoonoses (54). Furthermore, these brochettes should be consumed well done. It is also important to raise the awareness of involved stakeholders through education campaigns or media.

Conclusions

This study found the seroprevalence of brucellosis to be lower than the gold standard rate indicating that cut-off points of i-ELISA determined in Europe with brucellosis free status or low prevalence, should be optimized for Rwanda as also reported by Mathew *et al.* (2015). This study identified *B. abortus* and *B. melitensis* as well as mixed infection in slaughtered cattle which is as a result of the mixed livestock farming practice in Rwanda. These infections pose a risk of exposure potential to handlers of cattle, carcasses and consumers of unpasteurized milk and milk products. Thus, vaccination and test-and-slaughter would significantly contribute to mitigate the disease. Furthermore, the introduction of an annual brucellosis-free certificate for large herds would contribute to mitigating brucellosis in the country.

Author's contributions

Conceptualization, JBN, and HvH; methodology, JBN, and HvH; Formal analysis JBN; Investigation and data collection, JBN; Writing—original draft preparation, JBN; writing—review and editing, JBN, IEM, FBK, and HvH; Supervision, HvH, and FBK; Project administration, HvH; Resources, HvH; Funding acquisition, HvH. All authors have read and approved the manuscript.

Funding

This research was funded by the Institute of Tropical Medicine Antwerp, Belgium through a grant agreement with the Department of Veterinary Tropical Diseases, University of Pretoria, grant number ITM FA4.

Acknowledgments

The authors would like to acknowledge the Institute of tropical medicine, Belgium, and the Department of Veterinary Tropical Disease, South Africa, for funding the project. Our acknowledgments also go to the National Reference Laboratory, Department of Veterinary Services, and the University of Rwanda for the facilitation of this study. We also thank abattoir managers, inspectors and other abattoir workers, laboratory staff at NRL, and RAB for their assistance and good cooperation.

Conflict of interest

The authors declare that there are no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

Availability of Data

All data will be available in the supplementary material of this journal.

References

1. McDermott J, Grace D, Zinsstag J. Economics of brucellosis impact and control in low-income countries. *Revue Scientifique Et Technique-Office International Des Epizooties*. 2013;32(1):249-61.
2. Singh BB, Dhand NK, Gill JP. Economic losses occurring due to brucellosis in Indian livestock populations. *Prev Vet Med*. 2015;119(3-4):211-5.
3. Moreno E, Stackebrandt E, Dorsch M, Wolters J, Busch M, Mayer H. *Brucella abortus* 16S rRNA and lipid A reveal a phylogenetic relationship with members of the alpha-2 subdivision of the class Proteobacteria. *Journal of bacteriology*. 1990;172(7):3569-76.
4. Alton GG, Jones LM, Pietz DE. Laboratory techniques in brucellosis. 2d ed. ed. Geneva [Albany, N.Y.]: World Health Organization ; [Available from Q Corp.]; 1975.
5. Corbel MJ. Brucellosis: an overview. *Emerging infectious diseases*. 1997;3(2):213-21.
6. Verger J-M, Grimont F, Grimont PA, Grayon M. *Brucella*, a monospecific genus as shown by deoxyribonucleic acid hybridization. *International Journal of Systematic and Evolutionary Microbiology*. 1985;35(3):292-5.
7. Bricker BJ, Halling SM. Differentiation of *Brucella-Abortus-Bv-1*, *Brucella-Abortus-Bv-2*, and *Brucella-Abortus-Bv-4*, *Brucella-Melitensis*, *Brucella-Ovis*, and *Brucella-Suis-Bv-1* by PCR. *Journal of clinical microbiology*. 1994;32(11):2660-6.
8. Ficht T, Bearden S, Sowa B, Marquis H. Genetic variation at the *omp2* porin locus of the brucellae: species-specific markers. *Molecular microbiology*. 1990;4(7):1135-42.
9. OIE. Brucellosis (*Brucella abortus*, *Brucella melitensis*, and *Brucella suis*) Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2021. Volumes 1, 2 and 3. Terrestrial Manual 8th Edition, 2021 ed. Paris, France World Organisation for Animal Health 2021. p. 355 - 98.
10. Kaufmann AF, Fox MD, Boyce JM, Anderson DC, Potter ME, Martone WJ, et al. Airborne spread of brucellosis. *Annals of the New York Academy of Sciences*. 1980;353(1):105-14.
11. Corbel MJ. Brucellosis in humans and animals. Corbel MJ, editor2006. ix + 89 pp. p.
12. Akakpo A, Bornarel P. Epidemiology of animal brucellosis in tropical Africa: clinical, serological and bacteriological surveys. *Revue Scientifique et Technique de l'OIE (France)*. 1987.
13. Garcia-Yoldi D, Marin CM, de Miguel MJ, Munoz PM, Vizmanos JL, Lopez-Goni I. Multiplex PCR assay for the identification and differentiation of all *Brucella* species and the vaccine strains *Brucella abortus* S19 and RB51 and *Brucella melitensis* Rev1. *Clinical chemistry*. 2006;52(4):779-81.
14. Lopez-Goni I, Garcia-Yoldi D, Marin CM, de Miguel MJ, Munoz PM, Blasco JM, et al. Evaluation of a multiplex PCR assay (Bruce-ladder) for molecular typing of all *Brucella* species, including the vaccine strains. *Journal of clinical microbiology*. 2008;46(10):3484-7.
15. Ducrotoy MJ, Bardosh KL. How do you get the Rose Bengal Test at the point-of-care to diagnose brucellosis in Africa? The importance of a systems approach. *The Fate of Neglected Zoonotic Diseases*2017. p. 33-9.

16. Ndazigaruye G, Mushonga B, Kandiwa E, Samkange A, Segwagwe BE. Prevalence and risk factors for brucellosis seropositivity in cattle in Nyagatare District, Eastern Province, Rwanda. *Journal of the South African Veterinary Association*. 2018;89(0):e1-e8.
17. Ntivuguruzwa JB, Kolo FB, Gashururu RS, Umurerwa L, Byaruhanga C, van Heerden H. Seroprevalence and Associated Risk Factors of Bovine Brucellosis at the Wildlife-Livestock-Human Interface in Rwanda. *Microorganisms*. 2020;8(10):1553.
18. Gafirita J, Kiiza G, Murekatete A, Ndahayo LL, Tuyisenge J, Mashengesho V, et al. Seroprevalence of Brucellosis among Patients Attending a District Hospital in Rwanda. *The American Journal of Tropical Medicine and Hygiene*. 2017;97(3):831-5.
19. Rujeni N, Mbanzamihiho L. Prevalence of brucellosis among women presenting with abortion/stillbirth in Huye, Rwanda. *Journal of Tropical Medicine*. 2014;2014:740479-Article ID
20. Verger JM, Grayon M. [Characteristics of 273 strains of *Brucella abortus* of African origin]. *Dev Biol Stand*. 1984;56:63-71.
21. Minagri MoAaAR. Annual Report 2018 - 2019 Kigali, Rwanda MINAGRI; 2019 November 2019.
22. Dohoo IR, Martin SW, Stryhn H. *Veterinary epidemiologic research*. Charlotte, P.E.I.: VER, Inc.; 2009.
23. Pope GW. Determining the age of farm animals by their teeth: US Department of Agriculture; 1934.
24. Chisi SL, Marageni Y, Naidoo P, Zulu G, Akol GW, Van Heerden H. An evaluation of serological tests in the diagnosis of bovine brucellosis in naturally infected cattle in KwaZulu-Natal province in South Africa. *Journal of the South African Veterinary Association*. 2017;88(0):e1-e7.
25. Nielsen K. Diagnosis of brucellosis by serology. *Veterinary microbiology*. 2002;90(1-4):447-59.
26. Ledwaba MB, Matle I, Van Heerden H, Ndumnego OC, Gelaw AK. Investigating selective media for optimal isolation of *Brucella* spp. in South Africa. *Onderstepoort Journal of Veterinary Research*. 2020;87(1):1-9.
27. Keid LB, Soares RM, Vasconcellos SA, Chiebao DP, Salgado VR, Megid J, et al. A polymerase chain reaction for detection of *Brucella canis* in vaginal swabs of naturally infected bitches. *Theriogenology*. 2007;68(9):1260-70.
28. Garcia-Yoldi D, Marín C, Lopez-Goni I. Restriction site polymorphisms in the genes encoding new members of group 3 outer membrane protein family of *Brucella* spp. *FEMS microbiology letters*. 2005;245(1):79-84.
29. Vemulapalli R, McQuiston JR, Schurig GG, Sriranganathan N, Halling SM, Boyle SM. Identification of an IS711 Element Interrupting the *wboA* Gene of *Brucella abortus* Vaccine Strain RB51 and a PCR Assay To Distinguish Strain RB51 from Other *Brucella* Species and Strains. *Clinical and Diagnostic Laboratory Immunology*. 1999;6(5):760-4.
30. Cloeckert A, Grayon M, Grepinet O. An IS711 element downstream of the bp26 gene is a specific marker of *Brucella* spp. isolated from marine mammals. *Clinical and Diagnostic Laboratory Immunology*. 2000;7(5):835-9.

31. Vizcaino N, Verger J-M, Grayon M, Zygmunt MS, Cloeckaert A. DNA polymorphism at the omp-31 locus of *Brucella* spp.: evidence for a large deletion in *Brucella abortus*, and other species-specific markers. *Microbiology*. 1997;143(9):2913-21.
32. Rajashekara G, Glasner JD, Glover DA, Splitter GA. Comparative whole-genome hybridization reveals genomic islands in *Brucella* species. *Journal of bacteriology*. 2004;186(15):5040-51.
33. Sangari FJ, García-Lobo JM, Agüero J. The *Brucella abortus* vaccine strain B19 carries a deletion in the erythritol catabolic genes. *FEMS Microbiology Letters*. 1994;121(3):337-42.
34. Halling SM, Peterson-Burch BD, Bricker BJ, Zuerner RL, Qing Z, Li L-L, et al. Completion of the genome sequence of *Brucella abortus* and comparison to the highly similar genomes of *Brucella melitensis* and *Brucella suis*. *Journal of Bacteriology*. 2005;187(8):2715-26.
35. Cloeckaert A, Grayon M, Grépinet O. Identification of *Brucella melitensis* vaccine strain Rev.1 by PCR-RFLP based on a mutation in the rpsL gene. *Vaccine*. 2002;20(19):2546-50.
36. Rujeni N, Gasogo A, Mbanzamihiho L. Contribution to the Study of the Prevalence of Brucellosis in Rwanda. Case Study of Huye District. *International Journal of Infectious Diseases*. 2008;12(1):e128.
37. Awah-Ndukum J, Mouiche MMM, Bayang HN, Ngwa VN, Assana E, Feussom KJM, et al. Seroprevalence and Associated Risk Factors of Brucellosis among Indigenous Cattle in the Adamawa and North Regions of Cameroon. *Veterinary medicine international*. 2018;2018:3468596.
38. Akinseye VO, Adesokan HK, Ogugua AJ, Adedoyin FJ, Otu PI, Kwaghe AV, et al. Sero-epidemiological survey and risk factors associated with bovine brucellosis among slaughtered cattle in Nigeria. *Onderstepoort Journal of Veterinary Research*. 2016;83(1):1-7.
39. Kolo FB, Adesiyun AA, Fasina FO, Katsande CT, Dogonyaro BB, Potts A, et al. Seroprevalence and characterization of *Brucella* species in cattle slaughtered at Gauteng abattoirs, South Africa. *Veterinary Medicine and Science*. 2019;5(4):545-55.
40. Mangi M, Kamboh A, Rind R, Dewani P, Nizamani Z, Mangi A, et al. Seroprevalence of brucellosis in Holstein-Friesian and indigenous cattle breeds of Sindh Province. *Pakistan J Anim Health Prod*. 2015;3(4):82-7.
41. Omer M, Skjerve E, Woldehiwet Z, Holstad G. Risk factors for *Brucella* spp. infection in dairy cattle farms in Asmara, State of Eritrea. *Preventive Veterinary Medicine*. 2000;46(4):257-65.
42. Akhtar R, Iqbal MZ, Ullah A, Ali MM, Zahid B, Ijaz M, et al. Comparative association of *slc11a1* (*Nramp1*) gene with susceptibility and resistance to brucellosis in various cattle and buffaloes breeds of Pakistan. *Pak Vet J*. 2019;39:612-4.
43. Roux J. Epidémiologie et prévention de la brucellose. *Bulletin of the World Health Organization*. 1979;57(2):179.
44. Ducrotoy M, Bertu WJ, Matope G, Cadmus S, Conde-Alvarez R, Gusi AM, et al. Brucellosis in Sub-Saharan Africa: Current challenges for management, diagnosis and control. *Acta Tropica*. 2017;165:179-93.
45. Sadler WW. Present evidence on the role of meat in the epidemiology of human brucellosis. *American Journal of Public Health and the Nations Health*. 1960;50(4):504-14.

46. Sayour AE, Elbauomy E, Abdel-Hamid NH, Mahrous A, Carychao D, Cooley MB, et al. MLVA fingerprinting of *Brucella melitensis* circulating among livestock and cases of sporadic human illness in Egypt. *Transboundary and emerging diseases*. 2020;67(6):2435-45.
47. Mugizi DR, Muradrasoli S, Boqvist S, Erume J, Nasinyama GW, Waiswa C, et al. Isolation and molecular characterization of *Brucella* isolates in cattle milk in Uganda. *BioMed research international*. 2015;2015.
48. Mathew C, Stokstad M, Johansen T, Klevar S, Mdegela R, Mwamengele G, et al. First isolation, identification, phenotypic and genotypic characterization of *Brucella abortus* biovar 3 from dairy cattle in Tanzania. *BMC veterinary research*. 2015;11(1):156.
49. Muendo EN, Mbatha PM, Macharia J, Abdoel TH, Janszen PV, Pastoor R, et al. Infection of cattle in Kenya with *Brucella abortus* biovar 3 and *Brucella melitensis* biovar 1 genotypes. *Tropical animal health and production*. 2012;44(1):17-20.
50. Alton GG, Jones LM, Angus RD, Verger JM. *Techniques for the brucellosis laboratory* 1988. 190 pp. p.
51. Techoserve. The Dairy Value Chain in Rwanda Kigali Technoserve 2008 [cited 2020 October 8]. Available from: <https://cgspace.cgiar.org/bitstream/handle/10568/2410/Dairy%20Value%20Chain%20Rwanda%20Report.pdf;sequence=1>.
52. Caine L-A, Nwodo UU, Okoh AI, Green E. Molecular characterization of *Brucella* species in cattle, sheep and goats obtained from selected municipalities in the Eastern Cape, South Africa. *Asian Pacific Journal of Tropical Disease*. 2017;7(5):293-8.
53. Fero E, Juma A, Koni A, Boci J, Kirandjiski T, Connor R, et al. The seroprevalence of brucellosis and molecular characterization of *Brucella* species circulating in the beef cattle herds in Albania. *PloS one*. 2020;15(3):e0229741.
54. Vågsholm I. Control, monitoring and surveillance of animal health and animal infectious diseases at the slaughterhouse. *Meat Inspection and Control in the Slaughterhouse*. 2014:249-76.

Fig 2. Agarose gel electrophoresis of the 16-23S interspacer region (ITS) PCR products amplified from cultures of tissues from slaughtered cattle. Lanes M: DNA GeneRuler 100bp plus (Invitrogen, Pretoria, South Africa), lanes 1 – 7: amplification of a 214 bp sequence of the genus *Brucella* spp., lane 8: negative control containing sterile water, lane 9: positive control with *B. abortus* RF544.

Fig 3. Agarose gel electrophoresis for AMOS PCR products amplified from cultures of tissues from slaughtered cattle. Lanes M: Gene Ruler 100 pb plus (Invitrogen, ThermoFischer, South Africa), lanes 1-4: *Brucella abortus* (496 bp), lanes 5-7: *B. melitensis* (731 bp), Lanes 9-10: mixed *B. melitensis* and *B. abortus*, lane 11: negative control containing sterile water, lane 12: positive control, *B. abortus* RF544, lane 13: positive control, *B. melitensis* rev 1.

Fig 4. Agarose gel electrophoresis for Bruce-ladder PCR products amplified from cultures of tissues from slaughtered cattle. Lanes M: Gene Ruler 100 bp (Invitrogen, ThermoFischer, South Africa); lanes 1-5: *B. abortus*; lanes 6-8: *B. melitensis*; lane 9: positive control, *B. suis* ZW45, lane 10: positive control, *B. melitensis* rev 1, lane 11: *B. abortus* (REF 544), lane 12: positive control, *B. abortus* S 19, lane 13: negative control with sterile water.

Click here to access/download
Supporting Information
Raw data for PLOS ONE.xlsx